Publications by authors named "Miwako Asano"
Article Synopsis
- The study examined how natriuretic peptide levels changed in Asian heart failure patients treated with sacubitril/valsartan (S/V) compared to those on an angiotensin converting enzyme inhibitor (ACE-I).
- In the S/V group, the atrial natriuretic peptide (ANP) levels significantly increased and the dosage of loop diuretic furosemide decreased over six months, while the ACE-I group showed no such changes.
- Persistent atrial fibrillation and heart failure with preserved left ventricular ejection fraction were linked to higher ANP ratios, suggesting that S/V therapy enhances ANP levels in compensated heart failure patients.
Ongoing myocardial damage at the acme of the sepsis status has not been sufficiently evaluated. The clinical data of 160 sepsis patients who require intensive care and 127 outpatients with chronic heart failure (HF) were compared as a retrospective cohort study. Thereafter, the sepsis patients were divided into 3 groups according to the serum heart-type fatty acid-binding protein (H-FABP) quartiles [low H-FABP = Q1 (n = 39), middle H-FABP = Q2/Q3 (n = 81), and high H-FABP = Q4 group (n = 40)].
View Article and Find Full Text PDFWhether the dose of loop diuretics can be decreased by administration of a sodium-glucose cotransporter 2 (SGLT2) inhibitor in diabetic outpatients with compensated heart failure (HF) is unclear. This study prospectively enrolled 60 diabetic outpatients with compensated HF. Patients were randomly divided into 2 groups: those administered the SGLT2 inhibitor empagliflozin (n=28) and those not (n=30).
View Article and Find Full Text PDFThe mechanisms of the increased plasma xanthine oxidoreductase (XOR) activity in outpatients with cardiovascular disease were unclear. A total of 372 outpatients were screened, and 301 outpatients with cardiovascular disease were prospectively analyzed. Blood samples were collected from patients who visited a daily cardiovascular outpatient clinic.
View Article and Find Full Text PDFAims: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation.
Methods And Results: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood samples were collected within 15 min of admission from AHF patients (AHF group) and control patients who visited a daily cardiovascular outpatient clinic (control group).